Newsroom
Sorted by: Latest
-
INVESTOR ALERT: Securities Class Action Filed Against Veritone, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ:VERI) securities during the period of October 14, 2025 through April 14, 2026, inclusive (“the Class Period”).If you suffered a loss on your Veritone investments, you have until July 20, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted aft...
-
Daten aus der zulassungsrelevanten Studie zu EP0031 (A400), einem selektiven RET-Inhibitor (SRI) der nächsten Generation, bei RET-positivem fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) werden auf der ASCO 2026 vorgestellt
LONDON--(BUSINESS WIRE)--Ellipses Pharma („Ellipses“), ein weltweit tätiges Unternehmen für die Entwicklung von Krebsmedikamenten mit einer Pipeline innovativer Programme, gab heute bekannt, dass sein Partner, Kelun-Biotech, auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) vom 29. Mai bis 2. Juni in Chicago Daten aus einer zulassungsrelevanten Studie zu EP0031/A400 für die potenzielle Behandlung von RET-Fusions-positivem nicht-kleinzelligem Lungenkrebs (NSCLC) vorstell...
-
Nuvve Announces Receipt of Nasdaq Notice on Late Filing of Its Form 10-Q
SAN DIEGO--(BUSINESS WIRE)--Nuvve Holding Corp. (“Nuvve”) (Nasdaq:NVVE), a global leader in advanced energy storage, grid modernization solutions and vehicle-to-grid (V2G) technology, today announced that it received written notice (the “Notice”) on May 22, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Report”), i...
-
Riassunto: I dati dello studio clinico pivotale di EP0031 (A400), un inibitore selettivo di nuova generazione della chinasi RET (Selective RET Inhibitor - SRI), nel NSCLC metastatico positivo alla fusione di RET, verranno presentati all'ASCO 2026
LONDRA--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una società globale specializzata nello sviluppo di farmaci oncologici con una pipeline di programmi innovativi, ha annunciato oggi che il suo partner, Kelun-Biotech, sta presentando dati dallo studio clinico pivotale per EP0031/A400, per il potenziale trattamento del carcinoma polmonare non a piccole cellule (NSCLC) positivo alla fusione di RET, al Meeting annuale 2026 della American Society of Clinical Oncology (ASCO), che si terrà a Chic...
-
Resumen: Se presentarán en ASCO 2026 datos del estudio fundamental para EP0031 (A400), un inhibidor de RET selectivo (SRI) de próxima generación en NSCLC avanzado positivo para RET
LONDRES--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una empresa de desarrollo de fármacos oncológicos global con una cartera de programas innovadores, anunció hoy que su socio, Kelun-Biotech, está presentando datos del estudio fundamental de EP0031/A400 para el potencial tratamiento de cáncer de pulmón de células no pequeñas (NSCLC) avanzado positivo para RET, en la reunión anual de la American Society of Clinical Oncology (ASCO) 2026, que se llevará a cabo en Chicago del 29 de mayo al 2 de...
-
Virta Health Notice of Data Event
DENVER--(BUSINESS WIRE)--Virta Health Corp. and Virta Medical PC (hereinafter, collectively “Virta Health”) is providing this substitute notice as a result of a security incident to provide individuals with information and to share resources available for those who wish to further safeguard their personal information. The privacy and protection of information is a top priority for Virta Health. On March 24, 2026, Virta Health identified unauthorized activity limited to a data repository that is...
-
-
AOA Statement on HHS Dismissal of USPSTF Vice Chairs
CHICAGO--(BUSINESS WIRE)--Access to evidence-based preventive services is central to delivering whole-person care and supporting long-term patient wellbeing. Representing more than 207,000 osteopathic physicians (DOs) and medical students in the U.S., we are deeply concerned by the abrupt dismissal of the United States Preventive Services Task Force (USPSTF) Vice Chairs and political interference in the USPSTF process. The USPSTF plays a critical role in healthcare coverage and access to servic...
-
Super Micro Computer 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against Super Micro Computer, Inc. - SMCI
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in securities class action lawsuits against Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI), if they purchased or otherwise acquired the Company’s securities between February 2, 2024 and March 19, 2026, inclusive (the “Cl...
-
Scotts Miracle-Gro Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Scotts Miracle-Gro Company - SMG
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into The Scotts Miracle-Gro Company (NYSE: SMG) (“Scotts” or the “Company”). On August 2, 2023, the Company disclosed disappointing financial results including a decline in quarterly sales for fiscal third quarter of 6%, a decline in gross margin by 420 basis points, as well a...
